Abstract: A processor-implemented neural network method includes: determining a reference sample among sequential input samples to be processed by a neural network, the neural network comprising an input layer, one or more hidden layers, and an output layer; performing an inference process of obtaining an output activation of the output layer based on operations in the hidden layers corresponding to the reference sample input to the input layer; determining layer contraction parameters for determining an affine transformation relationship between the input layer and the output layer, for approximation of the inference process; and performing inference on one or more other sequential input samples among the sequential input samples using affine transformation based on the layer contraction parameters determined with respect to the reference sample.

Abstract: A processor-implemented neural network method includes: determining a reference sample among sequential input samples to be processed by a neural network, the neural network comprising an input layer, one or more hidden layers, and an output layer; performing an inference process of obtaining an output activation of the output layer based on operations in the hidden layers corresponding to the reference sample input to the input layer; determining layer contraction parameters for determining an affine transformation relationship between the input layer and the output layer, for approximation of the inference process; and performing inference on one or more other sequential input samples among the sequential input samples using affine transformation based on the layer contraction parameters determined with respect to the reference sample.

Abstract: Provided are novel human copper-zinc superoxide dismutase, also known as superoxide dismutase 1 or SOD1, specific antibodies as well as fragments, derivatives and variants thereof as well as methods related thereto. Assays, kits, and solid supports related to antibodies specific for SOD1 are also disclosed. The antibody, immunoglobulin chain(s), as well as binding fragments, derivatives and variants thereof can be used in pharmaceutical and diagnostic compositions for SOD1 targeted immunotherapy and diagnosis, respectively.

Abstract: An analysis apparatus (1) includes a housing unit (10) that houses a biological sample (S), a staining dispenser unit (20) that fluorescently stains the biological sample (S), an image acquisition unit (30) that acquires an image of the biological sample (S), a washer unit (40) that destains the biological sample (S), a drive unit (50), and a control unit (90) that analyzes the image and controls the drive unit (50). The control unit (90) performs adjustments so that the staining dispenser unit (20) and the housing unit (10) satisfy a first position condition, performs adjustments so that the image acquisition unit (30) and the housing unit (10) satisfy a second position condition, and performs adjustments so that the washer unit (40) and the housing unit (10) satisfy a third position condition. The analysis apparatus (1) maximizes the actual photography range of information related to the biological sample.

Abstract: The present application relates to fully humanized anti-FGFR4 single domain antibodies (sdAbs) and variants thereof. The present invention further relates to functionalized drug nanocarriers, nucleic acids, vectors, host cells, immune cells comprising said sdAbs, and compositions comprising thereof, as well as their use for therapy.

Abstract: Described are molecules specifically binding to human islet amyloid polypeptide (hIAPP) also known as amylin, particularly human-derived antibodies as well as fragments, derivatives and variants thereof for antagonizing islet amyloid polypeptide (IAPP) induced ?-cell damage and impaired glucose tolerance which are symptoms typically associated with diabetes mellitus type 2 (T2D).

Abstract: The present invention relates to methods for preventing or treating head and neck spuamous cell cancer and bladder cancer using an immunotoxin comprising (a) a ligand that binds to a protein on the cancer cell attached to; (b) a toxin that is cytotoxic to the cancer cell. In a specific embodiment, the invention is directed to the prevention or treatment of head and neck squamous cell cancer or bladder cancer using Vb4-845, which is a recombinant immunotoxin comprising a humanized, MOC31-derived, single-chain antibody fragment that is fused to a truncated form of Pseudomonas exotoxin A. Also encompassed by the invention are combination therapy methods, including the use of reduced dosages of chemotherapeutic agents, for the prevention or treatment of cancer. Also encompassed by the invention are formulations and methods for direct administration of the recombinant immunotoxin to the carcinoma, for the prevention or treatment of cancer.

Abstract: The present invention relates to methods for preventing or treating head and neck squamous cell cancer and bladder cancer using an immunotoxin comprising (a) a ligand that binds to a protein on the cancer cell attached to; (b) a toxin that is cytotoxic to the cancer cell. In a specific embodiment, the invention is directed to the prevention or treatment of head and neck squamous cell cancer or bladder cancer using Vb4-845, which is a recombinant immunotoxin comprising a humanized, MOC31-derived, single-chain antibody fragment that is fused to a truncated form of Pseudomonas exotoxin A. Also encompassed by the invention are combination therapy methods, including the use of reduced dosages of chemotherapeutic agents, for the prevention or treatment of cancer. Also encompassed by the invention are formulations and methods for direct administration of the recombinant immunotoxin to the carcinoma, for the prevention or treatment of cancer.

Abstract: Provided are novel human-derived antibodies specifically recognizing polyomavirus polypeptides, preferably capable of binding to polyomaviruses of the type of JC virus (JCV) and/or BK virus (BKV) as well as methods related thereto. Furthermore, assays and kits related to antibodies specific for polyomaviruses, polyomavirus VP1 and or polyomavirus VP1 Virus-Like Particles (VLPs), preferably of the type of JCV and/or BKV, are disclosed. The human-derived antibodies as well as binding fragments, derivatives and variants thereof can be used in pharmaceutical and diagnostic compositions for polyomavirus targeted immunotherapy and diagnostics.

Abstract: Disclosed is a neural network-based inference method and apparatus. The neural network-based inference method includes compressing a matrix comprising processing elements corresponding to an operation of a neural network, balancing workloads related to the operation by reordering the compressed matrix based on the workloads, and performing inference based on the reordered matrix.

Abstract: An analysis apparatus (1) includes a housing unit (10) that houses a biological sample (S), a staining dispenser unit (20) that fluorescently stains the biological sample (S), an image acquisition unit (30) that acquires an image of the biological sample (S), a washer unit (40) that destains the biological sample (S), a drive unit (50), and a control unit (90) that analyzes the image and controls the drive unit (50). The control unit (90) performs adjustments so that the staining dispenser unit (20) and the housing unit (10) satisfy a first position condition, performs adjustments so that the image acquisition unit (30) and the housing unit (10) satisfy a second position condition, and performs adjustments so that the washer unit (40) and the housing unit (10) satisfy a third position condition. The analysis apparatus (1) maximizes the actual photography range of information related to the biological sample.

Abstract: The present invention relates to methods for preventing or treating head and neck spuamous cell cancer and bladder cancer using an immunotoxin comprising (a) a ligand that binds to a protein on the cancer cell attached to; (b) a toxin that is cytotoxic to the cancer cell. In a specific embodiment, the invention is directed to the prevention or treatment of head and neck squamous cell cancer or bladder cancer using Vb4-845, which is a recombinant immunotoxin comprising a humanized, MOC31-derived, single-chain antibody fragment that is fused to a truncated form of Pseudomonas exotoxin A. Also encompassed by the invention are combination therapy methods, including the use of reduced dosages of chemotherapeutic agents, for the prevention or treatment of cancer. Also encompassed by the invention are formulations and methods for direct administration of the recombinant immunotoxin to the carcinoma, for the prevention or treatment of cancer.

Abstract: Provided are TAR DNA-binding protein of 43 kDa (TDP-43)-specific binding molecules including polypeptides such as human antibodies, as well as fragments, derivatives and variants thereof. Also provided are methods related to these TDP-43 specific binding molecules. Assays, kits, and solid supports related to TDP-43-specific binding molecules, including polypeptides such as, human antibodies are also disclosed. The TDP-43-specific binding molecule, antibody, immunoglobulin chain(s), as well as binding fragments, derivatives and variants thereof can be used in pharmaceutical and diagnostic compositions for TDP-43 targeted immunotherapy and diagnosis, respectively.

Abstract: Provided are novel human tau-specific antibodies as well as fragments, derivatives and variants thereof as well as methods related thereto. Assays, kits, and solid supports related to antibodies specific for tau are also disclosed. The antibody, immunoglobulin chain(s), as well as binding fragments, derivatives and variants thereof can be used in pharmaceutical and diagnostic compositions for tau targeted immunotherapy and diagnosis, respectively.

Abstract: The present invention relates to a nucleic acid molecule encoding a polypeptide conferring resistance to a plant against a fungal pathogen, such as Helminthosporium turcicum. The present invention further relates to a plant (or part thereof) comprising the nucleic acid molecule, and methods involving the nucleic acid molecule.

Abstract: The present invention relates to methods for preventing or treating head and neck squamous cell cancer and bladder cancer using an immunotoxin comprising (a) a ligand that binds to a protein on the cancer cell attached to; (b) a toxin that is cytotoxic to the cancer cell. In a specific embodiment, the invention is directed to the prevention or treatment of head and neck squamous cell cancer or bladder cancer using Vb4-845, which is a recombinant immunotoxin comprising a humanized, MOC31-derived, single-chain antibody fragment that is fused to a truncated form of Pseudomonas exotoxin A. Also encompassed by the invention are combination therapy methods, including the use of reduced dosages of chemotherapeutic agents, for the prevention or treatment of cancer. Also encompassed by the invention are formulations and methods for direct administration of the recombinant immunotoxin to the carcinoma, for the prevention or treatment of cancer.

Abstract: The present invention relates to methods for producing plants with increased fungal resistance, preferably seedling resistance against Northern Corn Leaf Blight. Further provided are methods for introducing, modifying, or modulating at least one wall-associated kinase (WAK) in(to) a plant cell, tissue, organ, or whole plant and thereby causing a reduced synthesis of benzoxazinoid and in turn increased fungal resistance. There are further provided methods to identify and/or modify downstream effector molecules in a WAK signalling cascade. Finally, plant cells, tissues, organs or whole plants having increased fungal resistance and methods using substances to activate signalling pathways in a targeted way are provided.

Abstract: A processor-implemented neural network method includes: determining a reference sample among sequential input samples to be processed by a neural network, the neural network comprising an input layer, one or more hidden layers, and an output layer; performing an inference process of obtaining an output activation of the output layer based on operations in the hidden layers corresponding to the reference sample input to the input layer; determining layer contraction parameters for determining an affine transformation relationship between the input layer and the output layer, for approximation of the inference process; and performing inference on one or more other sequential input samples among the sequential input samples using affine transformation based on the layer contraction parameters determined with respect to the reference sample.

Abstract: Provided are novel human ?-synuclein-specific antibodies as well as fragments, derivatives and variants thereof as well as methods related thereto. Assays, kits, and solid supports related to antibodies specific for ?-synuclein are also disclosed. The antibody, immunoglobulin chain(s), as well as binding fragments, derivatives and variants thereof can be used in pharmaceutical and diagnostic compositions for ?-synuclein targeted immunotherapy and diagnosis, respectively.

Abstract: Described are molecules specifically binding to human islet amyloid polypeptide (hIAPP) also known as amylin, particularly human-derived antibodies as well as fragments, derivatives and variants thereof for antagonizing islet amyloid polypeptide (IAPP) induced ?-cell damage and impaired glucose tolerance which are symptoms typically associated with diabetes mellitus type 2 (T2D).